From program compliance to claims management, AI holds promise as the next big thing for 340B program management assistance. Yet most people have yet to understand what AI truly is, and where it's just a marketing label on an otherwise normal software solution. For pharmacy directors, program managers, and consultants, the challenge isn’t just keeping up with the buzz, it’s knowing what actually works, what’s still theoretical, and what questions to ask of any vendor before believing the hype and jumping in. In this candid session led by lead AI product manager Hassan Bazzi and chief product officer Anthony Velasquez, we’ll unpack where AI does have the potential to simplify workflows, reduce administrative burden, and support better decision-making, and help you understand where it's mostly smoke and mirrors. You’ll leave with: - A realistic view of how AI could evolve in the 340B space over the next 6–12 months - Practical examples of early AI use cases (and what makes them actually useful) - Red flags to watch for when vendors overpromise or mislabel automation as “AI” - Key questions you should be asking when evaluating AI-powered tools for your program If you’re being asked to weigh in on AI, or want to be prepared when it inevitably shows up on your radar, this is the session you’ll want to attend.

Subscribers can join us for an exclusive webinar on June 18 from 12 to 1 p.m. ET, where you will hear from some of the nation’s top advocates and thought leaders on topics that include: ● Trump’s drug pricing executive orders, including one that has a number of elements focused specifically on 340B stakeholders. ● Next steps in Senate HELP Committee Chair Bill Cassidy’s (R-La.) 340B investigation. ● The future of the bipartisan SUSTAIN 340B Act and other 340B bills in Congress. ● Will drug manufacturers’ efforts to use a 340B rebate model instead of an upfront discount gain momentum or lose steam after a recent court decision?